Company Summary - Oxford BioMedica PLC (LSE:OXB)
3.20p
0.19p
(-5.94%)
FTSE Small Cap Pharmaceuticals & BiotechnologyMarket cap: £30.236m
NEW Explore our new and improved report for Oxford BioMedica PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Biopharmaceutical company engaged in the development of innovative gene-based medicines and therapeutic vaccines
| Financials - Interim (31/8/2011) | ||
|---|---|---|
| Turnover | £m | 4.95 |
| Pre-tax Profit | £m | -9 |
| EPS | p | -0.54 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Nick Rodgers | Chairman |
| John Dawson | Chief Executive |
| Tim Watts | Finance Director & Company Sec |
Products Brands & Subsidiaries
Products & Brands
Anti-5T4 antibody; EncorStat; EndoAngio-GT; Hi-8rMEL; MetXia; MoNuDin; ProSavin; RetinoStat; StarGen; TroVax; UshStat
Subsidiaries
BioMedica Inc; Oxford BioMedica (UK) Ltd
Broker Sentiment (2 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Management and Board change | 10/02/2012 |
| Notification of Major Interest in Sh... | 30/01/2012 |
| Directors' Interest in Shares | 16/12/2011 |
For more information
and investor relations, visit the
Oxford BioMedica PLC company website: